Aldeyra Therapeutics, Inc. (ALDX)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 8,505,229 | |||
| General and administrative | 1,663,503 | |||
| Loss from operations | -10,168,732 | |||
| Interest income | 872,038 | |||
| Interest expense | 470,618 | |||
| Total other income, net | 401,420 | |||
| Net loss | -9,767,312 | |||
| Earnings per share, basic | -0.16 | |||
| Earnings per share, diluted | -0.16 | |||
| Weighted average number of shares outstanding, basic | 60,045,530 | |||
| Weighted average number of shares outstanding, diluted | 60,045,530 | |||